Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | Western blot, luciferase reporter assay, etc. |
| Sample | acute myelocytic leukemia tissues, cell lines (HL-60, HEK-193T) |
| Expression Pattern | up-regulated |
| Function Description | it was demonstrated that the knockdown of lncRNA H19 resulted in increased expression of hsa-microRNA-19a/b and decreased expression of inhibitor of DNA binding 2 (ID2) in AML cells. |
| Pubmed ID | 28765931 |
| Year | 2017 |
| Title | LncRNA H19 regulates ID2 expression through competitive binding to hsa-miR-19a/b in acute myelocytic leukemia. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |